| Item number | Mass (g) | Volume (mL) | Size — height × width × depth (mm) | Surface area of device electrode (mm)2 | Distance between electrodes (mm) | Battery |
|---|---|---|---|---|---|---|
| LNQ22 | 3.4 | 1.4 | 45.1 × 8.0 × 4.2 | 16.0 | 40 | Lithium/silver vanadium oxide (SVO) and fluorinated carbon (CFx) cathode |
Insertable cardiac monitors
LINQ II™ insertable cardiac monitor
<p>The LINQ II™ insertable cardiac monitor (ICM) with AccuRhythm™ AI algorithms is used for long-term heart monitoring.</p>
Features
Clinically meaningful and actionable alerts
AccuRhythm™ AI algorithms for atrial fibrillation (AF) and pause further enhance the accuracy of LINQ II™ ICM data.3–5 The cloud-based AI system reduces false alerts while retaining true alerts, so clinicians can maintain diagnostic yield and spend more time on the human side of care.
AccuRhythm™ AI algorithms can seamlessly and remotely apply deep learning algorithms to new and already implanted LINQ II™ ICM devices. They were rigorously trained and were developed based on over one million professionally adjudicated ECGs for smarter, more accurate insight without data bias.3–6
Improving accuracy while maintaining sensitivity
AccuRhythm™ AI algorithms further address the two most common sources of these ICM false alerts — AF and pause.3,4,7
Validation on data from real-world LINQ II™ ICM patients demonstrated3,4:
97.4% reduction in false pause alerts
88.2% reduction in false AF alerts
Preserved true alerts3,4:
99% true AF alerts preserved
100% true pause alerts preserved
Reduce false alerts3,4
91% reduction in LINQ II™ ICM false alerts3
Discover how this impacts a clinic’s time. The AccuRhythm™ AI algorithms can save clinicians approximately 401 hours of false alert review yearly for every 200 LINQ II™ ICM patients.‡,§,3
Increased connectivity. Seamless experience.
BlueSync™ technology within the LINQ II™ ICM enables secure, wireless communication via Bluetooth®* Low Energy without compromising device longevity.1
- Reveal LINQ™ mobile manager
- LINQ II™ ICM
- MyCareLink Heart™ mobile app on patient’s smartphone or tablet, or
- MyCareLink Relay™ home communicator for bedside use
- CareLink™ network
- Medtronic Stay Connected service
Effortless connectivity
- Portable Bluetooth®* monitoring
- Monitor automatically detects if new data is available
- Event notification triggers an actionable alert
No manual transmissions
- Remote access to full ECGs eliminates the need for manual transmissions1
- Decreases patient action and confusion
Enhanced patient compliance
- Automatic smartphone notifications help patients stay connected
- Reduces clinic time spent on patient follow-up
MRI conditions for use: LINQ II™ ICM system
Conditionally safe MRI access SureScan™ technology
The LINQ II™ ICM is MR Conditional at ≤3T with no post-insertion waiting required.1
A patient with a LINQ II™ ICM can be safely scanned in an MR system that meets the following conditions with no post-insertion waiting required. Failure to follow these conditions for use may result in a hazard to the patient during an MRI scan1:
- Open or closed clinical MRI systems with a static magnetic field of ≤3T must be used.
- Hydrogen proton MRI equipment must be used.
- Maximum spatial gradient of the static magnetic field specification must be ≤ 25 T/m (2500 gauss/cm).
- Whole body gradient systems with gradient slew rate specification must be ≤ 200 T/m/s per axis.
- The Whole Body Specific Absorption Rate (WB-SAR) as reported by the MRI equipment must be ≤ 4.0 W/kg; the head SAR as reported by the MRI equipment must be ≤ 3.2 W/kg.
- Do not use local transmit coils on the chest, trunk, or shoulder region
- There are no restrictions on the placement of receive-only coils, and there are no restrictions on the use of local transmit or receive coils for imaging of the head or extremities.
For more information or to check MRI compatibility, visit the website below.
Patient data transmitted to the CareLink™ network via MyCareLink™ Relay or MyCareLink Heart™ app
Clinician-initiated reprogramming
via the CareLink™ network
Monitors act as a
pass-through
Device settings automatically update
without the need for an office visit
Ordering information
®* The Bluetooth®* word mark and logos are registered trademarks owned by Bluetooth SIG, Inc. and any use of such marks by Medtronic is under license.
† Nominal settings.
‡ The validation study performance and time study results were projected onto 16,301 LINQ II™ patients to calculate the time saved per year in 200 LINQ II™ ICM patients.
§ Estimated time savings was calculated based on 11.3 minutes per non-actionable ICM transmission.
¶ First European-approved (TÜV-notified body) remote programmable device.
- LINQ II LNQ22 ICM clinician manual. M974764A001D
- Ortega MM, Castrejon CS, Carton SA, et al. Miniaturized implantable loop recorders in a pediatric cohort. Europace. 2019;21(Supplement 2):¡563.
- Singh J, Radtke A, Rosemas S et al. Impact of enhanced artificial intelligence on clinic burden from false alerts of insertable cardiac monitors. Circulation 2023;148(Suppl 1):18672.doi: 10.1161/circ.148.suppl_1.18672.
- Cheng YJ, Ousdigian KT, Koehler J, Cho YK, Kloosterman M. Innovative artificial intelligence application reduces false pause alerts while maintaining perfect true pause sensitivity for insertable cardiac monitors. Heart Rhythm 2021;18(8) Suppl:S293-S294. doi: 10.1016/j.hrthm.2021.06.732.
- AccuRhythm™ AI clinical manual supplements. Medtronic.
- Radtke AP, Ousdigian KT, Haddad TD, Koehler JL, Colombowala IK. Artificial intelligence enables dramatic reduction of false atrial fibrillation alerts from insertable cardiac monitors. Heart Rhythm. 2021;18(S8) Suppl:S47. doi: 10.1016/j.hrthm.2021.06.137
- O’Shea CJ, Middeldorp ME, Hendriks JM, et al. Remote Monitoring of Implantable Loop Recorders: False-Positive Alert Episode Burden. Circ Arrhythm Electrophysiol. November 2021;14(11):e009635.
- Penela D, Fernández-Armenta J, Aguinaga L, et al. Clinical recognition of pure premature ventricular complex-induced cardiomyopathy at presentation. Heart Rhythm. 2017;14(12):1864–1870. doi: 10.1016/j.hrthm.2017.07.025.
- Penela D, Van Huls Van Taxis C, Aguinaga L, et al. Neurohormonal, structural, and functional recovery pattern after premature ventricular complex ablation is independent of structural heart disease status in patients with depressed left ventricular ejection fraction: a prospective multicenter study. J Am Coll Cardiol. 2013;62(13):1195–1202. doi: 10.1016/j.jacc.2013.06.012.